Keywords: biogen, bg-12, meets, psoriasis, endpoints, firm, idec

Biogen's BG-12 meets psoriasis endpoints

Article | 18 April 2005

Print This

US firm Biogen Idec and Fumapharm AG of Lausanne, Switzerland, have announced results from a Phase III study designed to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in